Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine

ACS Chemical Biology

Volumn 7, Issue 11, 2012, Pages 1910-1917

  Kwarcinski, Frank E ^a   Fox, Christel C ^a   Steffey, Michael E ^a   Soellner, Matthew B ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DASATINIB; ELECTROPHILE; PROTEIN TYROSINE KINASE INHIBITOR;

ANALYTIC METHOD; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEOMICS; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHICKENS; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES;

EID: 84869479566     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb300337u     Document Type: Article

References (37)

1. Levitzki, A. and Gazit, A. (1995) Tyrosine kinase inhibition-an approach to drug development Science 267, 1782-1788
2. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome Science 298, 1912-1934
3. Knight, Z. A. and Shokat, K. M. (2005) Features of selective kinase inhibitors Chem. Biol. 12, 621-637
4. Zhang, J. M., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9, 28-39
5. Leproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., and Winssinger, N. (2011) Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors J. Med. Chem. 54, 1347-1355
6. Barf, T. and Kaptein, A. (2012) Irreversible protein kinase inhibitors: balancing the benefits and risks J. Med. Chem. 55, 6243-6262
7. Singh, J., Petter, R. D., and Kluge, A. F. (2010) Targeted covalent drugs of the kinase family Curr. Opin. Chem. Biol. 14, 475-480
8. Thomas, S. M. and Brugge, J. S. (1997) Cellular functions regulated by Src family kinases Ann. Rev. Cell. Dev. Biol. 13, 513-609
9. Martin, G. S. (2001) The hunting of the Src Nat. Rev. Mol. Cell. Biol. 2, 467-475
10. Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., Sahin, A. A., Estevam, F. J., Hortobagyi, G. N., and Yu, D. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways Nat. Med. 17, 461-469
11. For a recent survey of kinase inhibitor selectivity, see: Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29, 1046-1051
12. Brandvold, K. B., Steffey, M. E., Fox, C. C., and Soellner, M. B. (2012) Development of a highly selective c-Src kinase inhibitor ACS Chem. Biol. 7, 1393-1398
13. Blair, J. A., Rauh, D., Kung, C., Yun, C.-H., Fan, Q.-W., Rode, H., Zhang, C., Eck, M. J., Weiss, W. A., and Shokat, K. M. (2007) Structure-guided probes for tyrosine kinases using chemical genetics Nat. Chem. Biol. 3, 229-238
14. Garske, A. L., Peters, U., Cortesi, A. T., Perez, J. L., and Shokat, K. M. (2011) Chemical genetic strategy for targeting protein kinases based on covalent complementary Proc. Natl. Acad. Sci. U.S.A. 108, 15046-15052
15. Statsuk, A. V., Maly, D. J., Seeliger, M. A., Fabian, M. A., Biggs, W. H., III, Lockhart, D. J., Zarrinkar, P. P., Kuryian, J., and Shokat, K. M. (2008) Tuning a three-component reaction for trapping kinase substrate complexes J. Am. Chem. Soc. 130, 17568-17574
16. Zhou, W., Hur, W., McDermott, L., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J., Meyerson, M., Settleman, J., and Gray, N. S. (2010) A structure-guided approach to creating covalent FGFR inhibitors Chem. Biol. 17, 285-295
17. Seeliger, M. A., Ranjitkar, P., Kasap, C., Shan, Y., Shaw, D. E., Shah, N. P., Kuriyan, J., and Maly, D. J. (2009) Equally potent inhibition of c-Src and c-Abl by compounds that recognize inactive kinase conformations Cancer Res. 69, 2384-2392
18. Krishnamurthy, R. and Maly, D. J. (2010) Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors ACS Chem. Biol. 5, 121-138
19. 50 values J. Biomol. Screening 14, 913-923
20. Reddick, J. J., Cheng, J., and Roush, W. R. (2003) Relative rates of Michael reactions of 2′-(phenyl)thiol with vinyl sulfones, vonyl sulfonate esters, and vinyl sulfonamides relevant to vinyl sulfone cysteine protease inhibitors Org. Lett. 5, 1967-1970
21. Hauck, C. R., Hsia, D. A., Puente, X. S., Cheresh, D. A., and Schlaepfer, D. D. (2002) FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth EMBO J. 21, 6289-6302
22. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A., Das, J., Doweyko, A. M., Farichild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J., and Borzilleri, R. M. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J. Med. Chem. 47, 6658-6661
23. Getlik, M., Grutter, C., Simard, J. R., Kluter, S., Rabiller, M., Rode, H. B., Robubi, A., and Rauh, D. (2009) Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc J. Med. Chem. 52, 3915-3926
24. Kluter, S., Simard, J. R., Rode, H. B., Grutter, C., Pawar, V., Raaijmakers, H. C. A., Bard, T. A., Rabiller, M., van Otterlo, W. A. L., and Rauh, D. (2010) Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance ChemBioChem 11, 2557-2566
25. Jester, B. W., Cox, K. J., Gaj, A., Shomin, C. D., Porter, J. D., and Ghosh, I. (2010) A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases J. Am. Chem. Soc. 132, 11727-11735
26. Jester, B. W., Gaj, A., Shomin, C. D., Cox, K. J., and Ghosh, I. (2012) Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen J. Med. Chem. 55, 1526-1537
27. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Woficka, L. M., and Zarrinkar, P. P. (2008) A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26, 127-132
28. Holbeck, S. L., Collins, J. M., and Doroshow, J. H. (2010) Analysis of FDA-approved anti-cancer agents in the NCI60 panel of human tumor cell lines Mol. Cancer Ther. 9, 1451-1460
29. Zheng, X., Resnick, R. J., and Shalloway, D. (2008) Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTPa and Src RNAi Int. J. Cancer 122, 1999-2007
30. For a recent review, see: Patel, R. Y. and Doerksen, R. J. (2010) Protein Kinase-inhibitor database: Structural variability of and inhibitor interactions with the protein kinase P-loop J. Proteome Res. 9, 4433-4442
31. Guimaraes, C. R. W., Rai, B. K., Munchhof, M. J., Liu, S., Wang, J., Bhattacharya, S. K., and Buckbinder, L. (2011) Understanding the impact of P-loop conformation on kinase selectivity J. Chem. Inf. Model. 51, 1199-1204
32. Hubbard, S. R. (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog EMBO J. 16, 5572-5581
33. Vajpai, N., Strauss, A., Fendrich, G., Cowan-Jacob, S. W., Manley, P. W., Grzesiek, S., and Jahnke, W. (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib J. Biol. Chem. 283, 18292-18302
34. Lee, T.-S., Potts, S. J., Kantarjian, H., Cortes, J., Giles, F., and Albitar, M. (2008) Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations Cancer 112, 1744-1753
35. Dixit, A. and Verkhiver, G. M. (2009) Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations PLoS Comp. Biol. 5, 1-22
36. Wang, Q., Cahill, S. M., Blumenstein, M., and Lawrence, D. S. (2006) Self-reporting fluorescent substrates of protein tyrosine kinases J. Am. Chem. Soc. 128, 1808-1809
37. Seeliger, M. A., Young, M., Henderson, M. N., Pellicena, P., King, D. S., Falick, A. M., and Kuriyan, J. (2005) High yield bacterial expression of active c-Abl and c-Src tyrosine kinases Protein Sci. 14, 3135-3139